scholarly journals The role of KPNA2 mutations in breast cancer prognosis: A survey of publicly available databases

2021 ◽  
Author(s):  
Layla Alnoumas ◽  
Lisa van den driest ◽  
Alison Lannigan ◽  
Caroline H Johnson ◽  
Nicholas JW Rattray ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Patient Survival ◽  
Chemotherapy Resistance ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
Therapeutic Interventions ◽  
Poor Patient ◽  
Patient Prognosis ◽  
The Uk

Breast cancer, comprising of several sub-phenotypes, is a leading cause of female cancer-related mortality in the UK and accounts for 15% of all cancer cases. Chemoresistant sub phenotypes of breast cancer remain a particular challenge. However, the rapidly-growing availability of clinical datasets, presents the scope to underpin a data driven precision medicine-based approach exploring new targets for diagnostic and therapeutic interventions. We report a survey of several publicly available databases probing the expression and prognostic role of Karyopherin-2 alpha (KPNA2) in breast cancer prognosis. Aberrant KPNA2 overexpression is directly correlated with aggressive tumour phenotypes and poor patient survival outcomes. We examined the existing information available on a range of commonly occurring mutations of KPNA2 and their correlation with patient survival. Our analysis of clinical gene expression datasets show that KPNA2 is frequently amplified in breast cancer, with differences in expression levels observed as a function of patient age and clinicopathologic parameters. We also found that aberrant KPNA2 overexpression is directly correlated with poor patient prognosis, warranting further investigation of KPNA2 as an actionable target for patient stratification or the design of novel chemotherapy agents. In the era of big data, the wealth of datasets available in the public domain can be used to underpin proof of concept studies evaluating the biomolecular pathways implicated in chemotherapy resistance in breast cancer.

scholarly journals Role of Cytological Grading in Breast Cancer Prognosis and its Histo-pathological Correlation

2014 ◽  
Vol 13 (10) ◽  
pp. 106-109
Author(s):  
Dr. Ruplekha Mitra Mustaphi ◽  
◽  
Dr. Surupa Chowdhury ◽  
Dr. Seema Mondal ◽  
Dr. Sugata Kumar Bhattacharya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
Pathological Correlation

The role of genetic variability in drug metabolism pathways in breast cancer prognosis

2006 ◽  
Vol 7 (4) ◽  
pp. 613-624 ◽  
Author(s):  
Ji-Yeob Choi ◽  
Susan A Nowell ◽  
Javier G Blanco ◽  
Christine B Ambrosone
Keyword(s):  
Breast Cancer ◽  
Genetic Variability ◽  
Drug Metabolism ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis

scholarly journals Obesity, leptin, and deregulation of microRNA in lipid metabolisms: their contribution to breast cancer prognosis

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Kartika W. Taroeno-Hariadi ◽  
Mardiah S. Hardianti ◽  
Hemi Sinorita ◽  
Teguh Aryandono
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Target Genes ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
Regulate Gene Expression ◽  
Non Coding Rna ◽  
Post Menopause ◽  
Points Of View

AbstractObesity and Metabolic Syndrome have been associated with cardiovascular, diabetes and cancer incidence. Obesity is a state of inflammation. There are cross-talks between adipocyte, adipokines, pro-inflammatory cytokines, insulin, leptin, and other growth factors to initiate signals for proliferation, anti-apoptosis, and angiogenesis. Those networks lead to cancer initiation, promotion, progression, and metastasis. Post menopause women with breast cancer commonly have overweight, obesity, and metabolic syndrome, which are previously reported as conditions to be associated with breast cancer prognosis. MicroRNAs (miRNAs), small non-coding RNA that regulate gene expression, are known to play important roles either in metabolic or carcinogenesis process in patients with breast cancer. Some miRNAs expressions are deregulated in persons either with obesity, breast cancer, or breast cancer with co-morbid obesity. This literature review aimed at reviewing recent publications on the role of obesity, leptin, and microRNA deregulation in adverse prognosis of breast cancer. Understanding the influence of deregulated miRNAs and their target genes in patients with breast cancer and obesity will direct more studies to explore the potential prognostic role of obesity in breast cancer from epigenetic points of view.

scholarly journals Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy

2020 ◽  
Vol 21 (15) ◽  
pp. 5207 ◽  
Author(s):  
Francesca Cersosimo ◽  
Silvia Lonardi ◽  
Giulia Bernardini ◽  
Brian Telfer ◽  
Giulio Eugenio Mandelli ◽  
...  
Keyword(s):  
Patient Survival ◽  
Survival Rates ◽  
Tumor Stroma ◽  
Therapeutic Management ◽  
Metastatic Progression ◽  
Tumor Associated Macrophages ◽  
Poor Patient ◽  
Metastasis Development ◽  
Patient Prognosis

Osteosarcomas (OSs) are bone tumors most commonly found in pediatric and adolescent patients characterized by high risk of metastatic progression and recurrence after therapy. Effective therapeutic management of this disease still remains elusive as evidenced by poor patient survival rates. To achieve a more effective therapeutic management regimen, and hence patient survival, there is a need to identify more focused targeted therapies for OSs treatment in the clinical setting. The role of the OS tumor stroma microenvironment plays a significant part in the development and dissemination of this disease. Important components, and hence potential targets for treatment, are the tumor-infiltrating macrophages that are known to orchestrate many aspects of OS stromal signaling and disease progression. In particular, increased infiltration of M2-like tumor-associated macrophages (TAMs) has been associated with OS metastasis and poor patient prognosis despite currently used aggressive therapies regimens. This review aims to provide a summary update of current macrophage-centered knowledge and to discuss the possible roles that macrophages play in the process of OS metastasis development focusing on the potential influence of stromal cross-talk signaling between TAMs, cancer-stem cells and additional OSs tumoral microenvironment factors.

scholarly journals Role of Genetic Variation in Cytochromes P450 in Breast Cancer Prognosis and Therapy Response

2021 ◽  
Vol 22 (6) ◽  
pp. 2826
Author(s):  
Viktor Hlaváč ◽  
Radka Václavíková ◽  
Veronika Brynychová ◽  
Pavel Ostašov ◽  
Renata Koževnikovová ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Genetic Variation ◽  
Cytochromes P450 ◽  
Disease Free Survival ◽  
Cytotoxic Chemotherapy ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
Free Survival ◽  
Disease Free

Breast cancer is the most frequent cancer in the female population worldwide. The role of germline genetic variability in cytochromes P450 (CYP) in breast cancer prognosis and individualized therapy awaits detailed elucidation. In the present study, we used the next-generation sequencing to assess associations of germline variants in the coding and regulatory sequences of all human CYP genes with response of the patients to the neoadjuvant cytotoxic chemotherapy and disease-free survival (n = 105). A total of 22 prioritized variants associating with a response or survival in the above evaluation phase were then analyzed by allelic discrimination in the large confirmation set (n = 802). Associations of variants in CYP1B1, CYP4F12, CYP4X1, and TBXAS1 with the response to the neoadjuvant cytotoxic chemotherapy were replicated by the confirmation phase. However, just association of variant rs17102977 in CYP4X1 passed the correction for multiple testing and can be considered clinically and statistically validated. Replicated associations for variants in CYP4X1, CYP24A1, and CYP26B1 with disease-free survival of all patients or patients stratified to subgroups according to therapy type have not passed a false discovery rate test. Although statistically not confirmed by the present study, the role of CYP genes in breast cancer prognosis should not be ruled out. In conclusion, the present study brings replicated association of variant rs17102977 in CYP4X1 with the response of patients to the neoadjuvant cytotoxic chemotherapy and warrants further research of genetic variation CYPs in breast cancer.

Sign in / Sign up

Export Citation Format

Share Document